Zoetis Inc. (NYSE:ZTS) Shares Acquired by Aaron Wealth Advisors LLC

Aaron Wealth Advisors LLC increased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 39.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,647 shares of the company’s stock after purchasing an additional 1,026 shares during the quarter. Aaron Wealth Advisors LLC’s holdings in Zoetis were worth $594,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Darwin Wealth Management LLC acquired a new stake in shares of Zoetis during the third quarter valued at about $31,000. First Personal Financial Services acquired a new stake in Zoetis in the 3rd quarter valued at approximately $33,000. Capital Performance Advisors LLP purchased a new stake in Zoetis in the third quarter valued at approximately $33,000. Dunhill Financial LLC lifted its stake in Zoetis by 80.6% during the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after purchasing an additional 75 shares in the last quarter. Finally, Quarry LP boosted its position in shares of Zoetis by 273.2% during the second quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after buying an additional 153 shares during the period. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Stock Performance

Shares of ZTS stock opened at $166.01 on Monday. The company has a market cap of $74.90 billion, a P/E ratio of 31.20, a PEG ratio of 2.51 and a beta of 0.89. The firm has a fifty day moving average price of $170.93 and a 200 day moving average price of $179.98. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $200.53.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.29 billion. During the same period in the prior year, the firm posted $1.36 EPS. The business’s quarterly revenue was up 11.6% compared to the same quarter last year. Sell-side analysts predict that Zoetis Inc. will post 5.91 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, January 21st will be given a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.20%. The ex-dividend date is Tuesday, January 21st. This is an increase from Zoetis’s previous quarterly dividend of $0.43. Zoetis’s payout ratio is currently 32.52%.

Analyst Upgrades and Downgrades

ZTS has been the topic of several research analyst reports. JPMorgan Chase & Co. boosted their price objective on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, October 11th. UBS Group initiated coverage on shares of Zoetis in a research note on Monday, December 9th. They set a “neutral” rating and a $196.00 price target on the stock. Stifel Nicolaus lowered their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, Leerink Partners started coverage on shares of Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target for the company. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $211.89.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.